Frontlight ResearchEarly access
Lung cancer trials in United Kingdom
152 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - Phase 3Taking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Cardiff, Edinburgh, London, Manchester, Sutton
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 1Taking peopleStudy of XB010 in Subjects With Solid Tumors
- Where
- Leicester, London, Manchester
- Age
- 18 years and over
- People
- 396 worldwide
- Run by
- Exelixis
See details and how to joinNCT06545331 - No phaseTaking peopleUnderstanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study
- Where
- Belfast
- Age
- 18 years and over
- People
- 30
- Run by
- Queen's University, Belfast
See details and how to joinNCT07554677 - Phase 3Taking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Birmingham, London, Manchester, Nottingham
- Age
- 18 years and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - Phase 3Taking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- London, Londonderry, Nottingham, Torquay
- Age
- 18 years and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne, Preston
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - Phase 1Taking peopleA Study of MGC026 in Participants With Advanced Solid Tumors
- Where
- Oxford, Sutton
- Age
- 18 years and over
- People
- 394 worldwide
- Run by
- MacroGenics
See details and how to joinNCT06242470 - Phase 3Taking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Cheltenham, Inverness, London, Norwich, Preston, Truro
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne, Torquay
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - Phase 1/2Taking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Cardiff, Leicester
- Age
- 18 years and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Birmingham, Guildford, London
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Cambridge, Coventry, London, Nottingham
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Eastbourne, London, Londonderry, Nottingham
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Aberdeen, Cambridge, Cardiff, Guildford, London, Middlesbrough, Norwich, Sutton, Wolverhampton
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - Phase 2Taking peopleA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Birmingham, Guildford, London
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Manchester
- Age
- 18 years and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - No phaseTaking peopleOptimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial
- Where
- Edinburgh, Gateshead, Liverpool
- Age
- 18 years and over
- People
- 118 worldwide
- Run by
- University of Edinburgh
See details and how to joinNCT07255066 - No phaseTaking peoplePRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Bristol, Edinburgh, Maidstone, Manchester, Nottingham, Sheffield, Sutton
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253 - Phase 3Taking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Cambridge, Chelsea, London, Nottingham, Stoke-on-Trent, Sutton, Wolverhampton
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - Phase 3Taking peopleSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Cambridge, Cardiff, Chelsea, Cottingham, Dundee, Exeter, Huddersfield, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Preston, Stoke-on-Trent, Sutton, Torquay, Wolverhampton
- Age
- 18 years and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Cambridge, Cardiff, London
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 1/2Taking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - Phase 3Taking peopleA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Cardiff, Manchester, Nottingham, Torquay
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00